Inflammaging: The Chronic Inflammation-Aging Connection and Evidence-Based Strategies

Inflammaging—the chronic, low-grade inflammation that accompanies biological aging—has emerged as a central driver of age-related decline, from cardiovascular disease to neurodegeneration. This state of persistent immune activation sits at the intersection of cellular senescence, metabolic dysfunction, and oxidative stress, making it one of the most clinically relevant targets for extending healthspan. While the term first gained traction in the early 2000s, it was the landmark hallmarks of aging framework that cemented its importance: López-Otín et al. (2013) classified deregulated nutrient sensing, cellular senescence, and altered intercellular communication—all tightly linked to chronic inflammation—as primary drivers of aging.

Inflammaging: The Research Landscape

Inflammaging is not a disease, but a biomarker-rich phenotype characterized by elevated circulating pro-inflammatory cytokines—typically two- to fourfold above youthful levels—in the absence of overt infection. The research landscape spans epidemiology, mechanistic studies in model organisms, and a growing body of human intervention trials. Most human evidence comes from cross-sectional studies showing that older adults have higher serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), even when excluding those with acute illness. What makes this body of data clinically actionable is that these markers are modifiable. A meta-analysis of randomized controlled trials by Gröber et al. (2015) found that magnesium supplementation consistently reduced CRP in individuals with low magnesium status, linking a common micronutrient deficiency directly to an inflammaging biomarker. This connection is explored in greater depth in our article on Magnesium and Inflammation: CRP.

Preclinical work has elucidated the underlying biology, often using aged mice or cellular senescence models. Mills et al. (2016) demonstrated that restoring NAD+ levels in old mice with long-term nicotinamide mononucleotide (NMN) reversed multiple age-associated physiological declines, many of which are mediated by inflammatory processes. Similarly, Ohsawa et al. (2007) identified molecular hydrogen as a selective antioxidant capable of suppressing the NF-κB pathway—the master switch of inflammatory gene expression—in cellular and animal models. While these findings are compelling, most human studies to date are small-scale or short-term, so the translation from bench to bedside remains an active area of investigation.

How Inflammaging Disrupts Cellular Homeostasis

At its core, inflammaging represents a failure of the immune system to resolve low-intensity inflammatory signals that accumulate over decades. A key upstream trigger is cellular senescence: as cells lose the ability to divide, they don’t simply die—they enter a state in which they secrete a cocktail of pro-inflammatory cytokines, chemokines, and matrix-degrading enzymes, collectively called the senescence-associated secretory phenotype (SASP). These SASP factors can spread inflammation to neighboring cells, fueling a vicious cycle that accelerates tissue dysfunction. López-Otín et al. (2013) specifically highlighted cellular senescence and its inflammatory output as one of the primary hallmarks of aging, and many of the other hallmarks—including mitochondrial dysfunction and stem cell exhaustion—feed directly into this cycle.

Mitochondrial decline is another major contributor. As the efficiency of oxidative phosphorylation drops with age, electron leak increases, producing excessive superoxide. This oxidative stress damages lipids and DNA, but it also activates the NLRP3 inflammasome, a protein complex that triggers the release of IL-1β and IL-18. Fang et al. (2017) reviewed how declining NAD+—a coenzyme essential for mitochondrial function and DNA repair—exacerbates this process, leaving cells more vulnerable to inflammatory challenges. In parallel, the NF-κB transcription factor, which is normally held in check by antioxidant defenses, becomes chronically activated. Ohsawa et al. (2007) showed that molecular hydrogen can selectively reduce the hydroxyl radicals that drive NF-κB activation, effectively uncoupling oxidative stress from inflammatory gene expression. This mechanism is so central that I’ve previously dissected it in detail in our piece on Hydrogen Water and Inflammation: NF-kB.

The net result of these molecular insults is a systemic shift toward a pro-inflammatory set point. Clinically, this manifests as elevated baseline CRP, higher neutrophil-to-lymphocyte ratios, and declining naïve T-cell populations—the very biomarkers we measure in ageing cohorts. Understanding these pathways clarifies why interventions that simultaneously address oxidative stress, NAD+ metabolism, and mineral status tend to show complementary effects rather than simply overlapping.

Evidence-Based Strategies to Counter Inflammaging

Given the multifactorial nature of inflammaging, the strongest evidence does not rest on a single silver bullet but on a stack of interventions that target distinct nodes of the inflammatory network. Below is a comparative overview of three interventions with mechanistic relevance and at least preliminary human or robust preclinical data.

Intervention	Primary Mechanism	Key Evidence	Typical Dose/Form	Observed Anti-Inflammatory Effect
Magnesium Glycinate	Lowers CRP, modulates calcium-dependent cytokine release	Gröber et al. (2015) – meta-analysis of RCTs	300–400 mg elemental magnesium/day	Significant CRP reduction in deficient/inflamed populations; benefits most pronounced when baseline CRP > 3 mg/L
Molecular Hydrogen (H₂)	Selective hydroxyl radical scavenging, NF-κB inhibition	Ohsawa et al. (2007) – Nature Medicine preclinical; small human pilot studies	H₂-rich water (0.5–1.6 mM), typically 1–2 L/day	Preclinical: reduced oxidative damage, suppressed NF-κB; human: trend toward lower IL-6 and 8-OHdG, but larger RCTs needed
Nicotinamide Mononucleotide (NMN)	Restores NAD+ pools, improves mitochondrial function, attenuates SASP	Mills et al. (2016) – Cell Metabolism in aged mice; ongoing human trials	Mice: 100–300 mg/kg/day; human equivalent under investigation	Improved insulin sensitivity, reduced adipose tissue inflammation, and normalized age-related gene expression in mice

Magnesium supplementation stands out because the human data are comparatively mature. The meta-analysis included in Gröber et al. (2015) encompassed individuals with prediabetes, metabolic syndrome, and hypomagnesemia, consistently showing that restoring magnesium to adequate levels dampened systemic inflammation. For example, in one included trial, 12 weeks of 300 mg/day magnesium reduced high-sensitivity CRP by 22% relative to placebo in overweight individuals with low dietary magnesium intake. Because magnesium deficiency is common in older adults—often due to reduced absorption and medication use—correcting this deficit is a low-risk, high-gain foundation for managing inflammaging.

Molecular hydrogen offers a mechanistically elegant, non-pharmacological approach. The seminal study by Ohsawa et al. (2007) showed that H₂ selectively neutralized peroxynitrite and hydroxyl radicals without quenching physiological signaling molecules like superoxide. This selectivity matters because low levels of reactive oxygen species serve essential functions in cellular communication; a broad-spectrum antioxidant would risk interfering with those signals. Through its effects on redox-sensitive kinases, hydrogen-rich water downregulates NF-κB and blunts the release of downstream cytokines. While the human evidence remains limited to pilot studies and small-scale trials, the safety profile and mechanistic rationale are strong. For those who want to explore this pathway, PEPAX Blueberry Hydrogen Water Tablets deliver a standardised dose of dissolved molecular hydrogen in water—no bulky generators required—making daily use straightforward. To understand the NF-κB connection better, you can revisit our dedicated write-up on Hydrogen Water and Inflammation: NF-kB.

NMN’s relevance to inflammaging ties into the broader Hallmarks of Aging framework. Mills et al. (2016) reported that aged mice given NMN for 12 months exhibited restored NAD+ levels in skeletal muscle and liver, accompanied by reductions in adipose tissue inflammation and markers of cellular senescence. While these are mouse data—and therefore must be interpreted cautiously—they align with the biological principle that NAD+ acts as a co-substrate for sirtuins and PARPs, enzymes that directly modulate inflammatory gene expression. As discussed in our article on NMN and Immune Function, emerging evidence also points to NAD+’s role in preserving T-cell function, which gradually declines during immunosenescence.

Who Benefits Most from Inflammaging Interventions?

The principle of targeting inflammaging is not one-size-fits-all. The strongest human evidence for benefit exists in populations with documented, subclinical elevations in inflammatory markers or known micronutrient insufficiencies. Specifically:

• Older adults with a CRP above 2 mg/L and low magnesium intake: This group shows the most reliable CRP reductions with magnesium supplementation, sometimes achieving a drop of 0.5–1.0 mg/L, which is clinically meaningful given that each 1 mg/L increase in CRP is associated with a roughly 20% higher cardiovascular event risk.
• Individuals with metabolic syndrome or prediabetes: Chronic low-grade inflammation is a hallmark of insulin resistance, and both magnesium and hydrogen-rich water have shown preliminary improvements in metabolic parameters—though the latter requires larger trials.
• Those exposed to high oxidative stress—whether from intensive exercise, environmental pollutants, or chronic psychological stress—may benefit from hydrogen water’s selective antioxidant action, as oxidative damage and inflammation form a self-reinforcing loop.
• Adults wishing to support NAD+ and immune resilience: While human efficacy data for NMN are pending, the preclinical profile and the well-established safety of B3 vitamers make this a rational option for those with a strong family history of age-related disease, provided they understand the evidentiary uncertainty.

Importantly, none of these strategies replace foundational lifestyle measures. A diet rich in polyphenols, omega-3 fatty acids, and adequate protein, combined with regular physical activity and 7–8 hours of sleep, remains the most robust, evidence-backed strategy for lowering chronic inflammation. Supplements work best when layered on top of that foundation rather than substituted for it.

Practical Takeaways for Managing Inflammaging

Based on the available evidence, here are five actionable steps to mitigate inflammaging:

• Check your biomarkers. Measuring high-sensitivity CRP and serum magnesium provides a data-driven starting point. If CRP is persistently above 1–2 mg/L and magnesium is in the low-normal range (<0.85 mmol/L), targeted intervention is justified.
• Optimise magnesium status first. For those with low dietary intake, 300–400 mg of elemental magnesium as glycinate or citrate can lower CRP and improve insulin sensitivity. Monitor renal function if doses exceed 400 mg/day.
• Consider molecular hydrogen as an adjunctive antioxidant. 1–2 litres of hydrogen-rich water at ~1 mM concentration daily can help keep NF-κB activation in check. Because hydrogen is a gas, timing matters—drink it soon after generation for maximum H₂ content.
• Explore NAD+ precursors with caution. If you opt for NMN, look for third-party tested products and stay updated on human RCT results. Pairing NMN with lifestyle measures that naturally boost NAD+ (exercise, intermittent fasting) may synergise.
• Reassess every 3–6 months. Repeat inflammatory markers to see if the interventions are working. CRP is responsive within weeks; changes in immune cell subsets take longer. Adjust your protocol based on objective data, not subjective feeling alone.

Bottom Line on Inflammaging

Inflammaging is a real, measurable phenomenon that bridges the gap between cellular aging and clinical disease. The human evidence for magnesium’s ability to lower CRP is solid and immediately applicable. Molecular hydrogen and NMN rest on compelling mechanistic grounds and positive preclinical studies, but their human outcomes literature is still maturing; they should be viewed as promising, not proven, adjuncts. The smartest clinical approach combines biomarker monitoring with a layered strategy—fixing a magnesium deficit, supporting the body’s antioxidant capacity with hydrogen, and addressing NAD+ decline where biologically plausible—while never losing sight of the power of diet, sleep, and exercise to quench the slow burn of chronic inflammation.

---

References

1. López-Otín C, et al. "The Hallmarks of Aging." Cell. 2013;153(6):1194–1217. [Source]
2. Fang EF, et al. "NAD+ in Aging: Molecular Mechanisms and Translational Implications." Trends in Molecular Medicine. 2017;23(10):899–916. [Source]
3. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism. 2016;24(6):795–806. [Source]
4. Gröber U, et al. "Magnesium in Prevention and Therapy." Nutrients. 2015;7(9):8199–8226. [Source]
5. Ohsawa I, et al. "Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals." Nature Medicine. 2007;13(6):688–694. [Source]

---

---